Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
The French drug company Servier will buy Shire’s cancer-drug business for $2.4 billion. Shire’s marketed products for leukemia and pancreatic cancer represent less than 2% of the rare-disease drug company’s sales. Shire also has an experimental treatment for leukemia under review at the U.S. FDA. News of the sale comes about two weeks after Japan’s Takeda Pharmaceutical announced it was considering a bid to acquire Shire.
This article has been sent to the following recipient: